Rituximab

Drug Profile

Rituximab

Alternative Names: IDEC-102; IDEC-C2B8; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; Rituximab/hyaluronidase subcutaneous injection; RO-452294

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Halozyme Therapeutics; Hoosier Cancer Research Network; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Preregistration Haematological malignancies
  • Phase III Mantle-cell lymphoma; Pemphigus vulgaris; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B cell lymphoma
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Immune thrombocytopenic purpura; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 29 Mar 2017 The FDA's Oncologic Drugs Advisory Committee voted unanimously favouring the benefits of rituximab and hyaluronidase subcutaneous co-formulation for the treatment of various Haematological cancers
  • 24 Mar 2017 Rituximab receives Breakthrough Therapy status for Pemphigus vulgaris in USA
  • 01 Feb 2017 Genetech terminates a phase III trial in Nephrotic syndrome (In infants, In children, In adolescents) in USA as the sponsor milestones and financing requirements could not be met (NCT02390362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top